After more than two years of intense effort, Sun Pharma has returned its key plant to the good graces of the FDA.
Next stop on WuXi Biologic's rapid advance in biologics manufacturing is the Boston, Massachusetts area where it will build a $60 million facility.
Takeda shareholders who oppose the company’s $62 billion buyout of Shire are gaining support for their effort to block the deal.
Experts say China's data sharing rule may hinder drug R&D; FDA rejects Mylan and Biocon's Lantus biosim and more news.
A leading position in insulin, combined with new launches like GLP1 drug Victoza, could help Novo grow to DKK19 billion in China by 2025.
Turnaround efforts at IDT Australia now include an FDA warning letter.
Zai's new chief commercial officer, William Liang, oversaw the launch of Tagrisso in China, and had oncology leadership stints at BMS and Roche.
When Roche got Herceptin onto China’s insurance list, it didn’t expect demand to surge so fast. Now, it's shifting to a new plant to boost supplies.
The FDA has issued a complete response letter to partners Biocon and Mylan for their version of Sanofi’s blockbuster Lantus insulin.
Takeda investors voice concerns over Shire deal; WuXi AppTec becomes the largest-cap CRO; two families' wealth swells on Gardasil nods.